Table 1. Cell death measured by annexin V assay and mitochondrial transmembrane potential (MTP) assay in endometrial cancer cell lines.

	Cell Line		Vehicle	Telmisartan (100 μM)
Annexin V assay	Ishikawa	Viable (LL) (%)	87.1±2.9	60.4±0.6**
		Early Apoptosis (LR) (%)	2.2±1.5	3.1±1.1
		Late Apoptosis (UR) (%)	6.2±0.6	20.0±1.8**
	HEC-59	Viable (LL) (%)	87.2±6.8	42.1±9.6 **
		Early Apoptosis (LR) (%)	4.2±1.7	4.8±2.9
		Late Apoptosis (UR) (%)	3.4±2.1	14.7±2.7**
	HHUA	Viable (LL) (%)	92.9±1.8	43.1±7.6**
		Early Apoptosis (LR) (%)	2.9±0.6	6.6±2.0
		Late Apoptosis (UR) (%)	1.2±0.4	12.0±3.1*
MTP assay	Ishikawa	Viable (%)	86.9±4.9	70.7±5.1*
		Apoptosis (%)	13.5±5.1	30.1±5.3*
	HEC-59	Viable (%)	98.8±0.3	78.8±0.1**
		Apoptosis (%)	1.3±0.3	21.7±0.1**
	HHUA	Viable (%)	92.7±1.4	73.1±0.4**
		Apoptosis (%)	7.5±1.4	27.3±0.4**

Endometrial cancer cells were treated with 100 μM of telmisartan for 48 h. Cells were then stained with annexin V and PI (propidium iodide). The positive cells were detected by flow cytometry. The viable cells were negative for both annexin V and PI staining (the lower left quadrant of the cytograms, LL), the early apoptotic cells were positive for annexin V staining but negative for PI staining (the lower right quadrant, LR), and the late apoptotic cells were positive for both annexin V and PI staining (the upper right quadrant, UR). MTP results were analyzed using the MitoCapture assay. Endometrial cancer cells were treated with telmisartan for 48 h and harvested for flow cytometry. Each experiment was repeated three times. Results = means ± SD of three independent experiments. *P<0.05, **P<0.01 vs. the control group.